| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cost of Revenue | $0 | — |
| R&D Expense | $19.1M | -20.5% |
| SG&A Expense | $12.4M | -10.4% |
| Operating Income | -$31.5M | +16.8% |
| Pre-tax Income | -$30.9M | +17.3% |
| Income Tax | $0 | — |
| Net Income | -$30.9M | +17.3% |
| EPS (Basic) | -$0.50 | +62.7% |
| EPS (Diluted) | -$0.50 |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $13.9M | +448.9% |
| Current Assets | $16.3M | +414.7% |
| Total Assets | $19.4M | +212.5% |
| Current Liabilities | $9.5M | -30.8% |
| Total Liabilities | $10.0M | -29.8% |
| Stockholders' Equity | $9.5M | +218.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$35.4M | -12.7% |
| Investing Cash Flow | $0 | +100.0% |
| Financing Cash Flow | $46.8M | +109.5% |
| +62.7% |